This study evaluates the risk of stroke (ischemic or hemorrhagic) and myocardial infarction (MI) among postmenopausal women and men initiating osteoporosis treatment with denosumab (RANKL inhibitor) or zoledronic acid (bisphosphonate). The gene discussed is TNFSF11; the disease is myocardial infarction.